evoxx technologies: biotechnology for healthy nutrition

Following the acquisition of aevotis GmbH by evocatal GmbH in January 2015, the two are now legally merged and operating as evoxx technologies GmbH

Biotechnology companies evocatal and aevotis have merged, forming evoxx technologies to focus on the development of enzymes and carbohydrate ingredients for the functional food market (nutritional health and wellness).

A strong patent protected technology platform enables the development and marketing of exclusive carbohydrate oligomers/polymers for the global food market.

Following the acquisition of aevotis GmbH by evocatal GmbH in January 2015, the two are now legally merged and operating as evoxx technologies GmbH with the vision to become a leading provider of innovative enzyme and carbohydrate products for the food market.

'In the functional food market, we see an increasing demand for novel ingredients with strong scientifically supported health benefits,' describes Dr Thorsten Eggert, Managing Director (CEO). To meet the needs of its customers, the food industry needs novel and multifunctional ingredients that are in line with recent scientific findings and studies on healthy diets.

'A combination of convenience and health is required,' states Martina Doering, Managing Director (CSO). 'Modern consumers expect food to deliver health benefits with the same taste and eating behaviour,' she continues.

evoxx technologies GmbH will use its competitive enzyme and carbohydrate development expertise in applications where high sugar content (sucrose, glucose, fructose, etc.) and/or inadequate amount of dietary fibre requires a solution.

The company’s vision, as summarised by Dr Eggert, is as follows: 'Within the next 3 years, evoxx will bring more healthy carbohydrates into the glass and onto the plate of the consumer by using enzymes and ingredients from the evoke pipeline.'

Notwithstanding the new market focus, evoxx will ensure continuity in co-operative projects with customers and partners. The proprietary technology platform of evocatal and aevotis will still be applied by evoxx technologies to develop tailor-made enzymes and processes for various industries. evoxx technologies plans to enhance production capability to supply enzymes on an industrial scale for current and future customers.